Jubilant Pharmova's Q4 FY 2025-26 Quarterly Results

Result Summary

• Jubilant Pharmova Ltd reported a 8.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 19.2%.
• Its expenses for the quarter were up by 5.7% QoQ and 22.7% YoY.
• The net profit increased 113.8% QoQ and decreased 21.2% YoY.
• The earnings per share (EPS) of Jubilant Pharmova Ltd stood at 7.52 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Jubilant Pharmova Ltd is a prominent player in the pharmaceutical industry, known for its diverse portfolio of products and services. The company focuses on developing, manufacturing, and supplying a range of pharmaceuticals, including APIs, generics, specialty pharmaceuticals, and nutraceuticals. Jubilant Pharmova also offers contract research and manufacturing services to other pharmaceutical companies. As a part of its strategic initiatives, the company consistently invests in research and development to enhance its product offerings and maintain competitive strength. Recent developments and strategic partnerships could influence its market position and operational focus, but specific recent events are not detailed in the provided data.

Revenue

In the fourth quarter of fiscal year 2026, Jubilant Pharmova Ltd reported a total income of ₹2313.70 crores, marking an 8.0% increase compared to the previous quarter's total income of ₹2143.00 crores. When compared year-over-year to the fourth quarter of fiscal year 2025, which recorded a total income of ₹1940.70 crores, the company experienced a growth of 19.2%. This upward trend in revenue highlights a consistent performance in terms of income generation over the year. The quarter-over-quarter increase indicates a positive trajectory in the company's revenue stream for this period.

Profitability

Jubilant Pharmova Ltd's profitability metrics for Q4FY26 demonstrate significant variations. The profit before tax for the quarter was ₹176.00 crores, showing an 88.2% increase from the previous quarter's ₹93.50 crores. However, compared to the same quarter in the previous year, there is a decrease of 14.6% from ₹206.10 crores. The tax expense for Q4FY26 was ₹56.70 crores, up by 50.8% from Q3FY26's ₹37.60 crores, and a slight increase of 3.7% from Q4FY25's ₹54.70 crores. Profit after tax stood at ₹119.30 crores, which represents a substantial quarter-over-quarter increase of 113.8% from ₹55.80 crores, but a year-over-year decline of 21.2% from ₹151.30 crores. The earnings per share (EPS) followed a similar pattern, reaching ₹7.52, which is an increase of 113.6% from the previous quarter, yet a decline of 22.3% from the same quarter last year.

Operating Metrics

The total expenses for Jubilant Pharmova Ltd in Q4FY26 were ₹2124.00 crores, which is a 5.7% increase from the previous quarter's expenses of ₹2009.80 crores and a 22.7% rise from the previous year's fourth quarter expenses of ₹1731.30 crores. These operating metrics indicate changes in the cost structure of the company over the quarters and year. The data points towards varying dynamics in expense management and operational efficiency, as reflected in the reported figures. While the total expenses have increased both quarter-over-quarter and year-over-year, the company has managed to improve its income over the same periods, impacting its operating results.